While the Alzheimer’s world fights over whose IV infusion clears amyloid plaques faster, Alzheon just quietly dosed the first subject in a Phase 1 trial of ALZ-507 — an oral small molecule that goes after soluble amyloid oligomers and packs an APOE4-corrector mechanism. Once-daily pill. No infusion centers. No monitoring windows.

That APOE4 angle matters. Carriers of the APOE4 allele are at dramatically higher risk for Alzheimer’s, and most anti-amyloid therapies don’t differentiate by genotype. Alzheon has built its entire thesis around this population — their Phase 3 asset ALZ-801 (valiltramiprosate) ran its pivotal APOLLOE4 trial specifically in APOE4/4 homozygotes, and the biomarker data showed p-tau217 reductions that correlated with cognitive improvements.

Now ALZ-507 enters the picture as the second oral anti-amyloid asset in Alzheon’s portfolio. The Phase 1 SAD/MAD study is in healthy volunteers — standard first-in-human stuff — but the strategic picture is bigger. This gives Alzheon a two-asset oral pipeline in a space dominated by monoclonal antibodies that require IV infusion, ARIA monitoring, and specialty clinic infrastructure.

The competitive landscape is getting interesting. Korsana Biosciences is working on a next-gen shuttled antibody (KRSA-028) designed to cross the blood-brain barrier more efficiently. MindImmune is going after neuroinflammation with a completely different mechanism — blocking peripheral immune cell recruitment into the brain. And the big players like Eisai and Lilly continue to push their IV platforms globally.

But Alzheon’s bet is that the future of Alzheimer’s treatment looks more like a daily pill than a biweekly infusion. If ALZ-801’s Phase 3 data holds up and ALZ-507 advances, they’ll have something nobody else does: two differentiated oral mechanisms targeting the highest-risk patient population. That’s a portfolio thesis, not a one-shot gamble.